{"id":828480,"date":"2025-03-21T08:35:04","date_gmt":"2025-03-21T12:35:04","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/silexion-therapeutics-announces-completion-of-innovative-expanded-development-plan-for-sil204-which-will-be-unveiled-at-the-2025-neauxcancer-conference\/"},"modified":"2025-03-21T08:35:04","modified_gmt":"2025-03-21T12:35:04","slug":"silexion-therapeutics-announces-completion-of-innovative-expanded-development-plan-for-sil204-which-will-be-unveiled-at-the-2025-neauxcancer-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/silexion-therapeutics-announces-completion-of-innovative-expanded-development-plan-for-sil204-which-will-be-unveiled-at-the-2025-neauxcancer-conference\/","title":{"rendered":"Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference"},"content":{"rendered":"<h2>\nSilexion Therapeutics to Present Innovative New Expanded Development Plan for SIL204 at the Industry Leading 2025 NeauxCancer Conference, Following Recently Reported Groundbreaking Preclinical data from Orthotopic Models; Further Details about the Plan to be Reported Shortly Alongside the Presentation<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p>Grand Cayman, Cayman Islands, March  21, 2025  (GLOBE NEWSWIRE) &#8212; Silexion Therapeutics Corp. (\u201cSilexion\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers,\u00a0today announced it has completed an expanded development plan for its next-generation siRNA candidate, SIL204, which the company\u2019s management will be presenting at the upcoming Cancer Advocacy Group of Louisiana (CAGLA) NeauxCancer 2025 Conference being held March 27th-29th, 2025 at The Roosevelt New Orleans Hotel in New Orleans, LA.<\/p>\n<p>The newly completed strategic plan builds upon Silexion&#8217;s recent promising preclinical data and is designed to maximize SIL-204&#8217;s potential across multiple delivery approaches to address the challenges of KRAS-driven cancers. The Company plans to report further details on the expanded plan alongside its presentation at the conference.<\/p>\n<p>A company presentation will take place during the conference&#8217;s Innovation track on Friday, March 28th at 1:00pm. During this session, Silexion will present its strategic vision alongside recently reported preclinical findings from its SIL-204 program.<\/p>\n<p>&#8220;We look forward to sharing our expanded development plan for SIL-204 at the upcoming NeauxCancer Conference,&#8221; said Ilan Hadar, Chairman and CEO of Silexion Therapeutics. &#8220;Recent advances in our preclinical program have informed a more comprehensive approach to targeting KRAS-driven cancers, particularly pancreatic cancer. Our presentation will outline how we plan to leverage these findings to advance SIL-204 toward clinical development.&#8221;<\/p>\n<p>Silexion&#8217;s management team will be available for one-on-one meetings during the conference. Interested investors should contact Silexion&#8217;s investor relations representatives as listed below.<\/p>\n<p>\n        <strong>About Silexion Therapeutics<br \/><\/strong>Silexion Therapeutics is a pioneering clinical-stage, oncology-focused biotechnology company developing innovative RNA interference (RNAi) therapies to treat solid tumors driven by KRAS mutations, the most common oncogenic driver in human cancers. The company&#8217;s first-generation product, LODER\u2122, has shown promising results in a Phase 2 clinical trial for non-resectable pancreatic cancer. Silexion is also advancing its next-generation siRNA candidate, SIL204, designed to target a broader range of KRAS mutations and showing significant potential in preclinical studies. The company remains committed to pushing the boundaries of therapeutic innovation in oncology, with a focus on improving outcomes for patients with difficult-to-treat cancers. For more information please visit:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=F2x33gCWjwdaDDxS3KitJ58dotSiBPXyRcZHT2mVJNMSKtpAKkMgVnblSRDdo58nwWzCSOQJXdBSa1X9eNZKhgnaDYVf1zMS0q0IX4jTAJ85IegeSuerVnahkZ0c82kDixkt18Fd5jCBXDmfjC-s_GW9JhhqAIv-9IcW6YWDn_ouGbaPRRzEHyvJ8mmhNsCHSE8mXUR27L3GPT18jrIkkrCe8LACd2_OZ7Y4XFMugAw9Ad7ZbKS_9Ubtpuc623ot20f0FaWh2m3RC4AKApe8AdE4k_Y-icxlay3FCChVN_LvgwLDSB12lFc617wLEpEc7C7FM7348S5h88Y594Zqssf4TObkFVOOF0PXYbZ_viwSHM1llMMWqikNaymvJJwYo50T3Xz9KMe873RviSvTbmSgbykx5G28wBrOZ4WDv_ZfdvZZeiZKlfFW-eeztAPAj0O-VFCS9W4jCn44M71Tdw6n7Z9FJ8tXcdyPrkIEZjqk2Zg1iCvwm0p9QByyCmGW\" rel=\"nofollow\" target=\"_blank\">https:\/\/silexion.com<\/a><\/p>\n<p>\n        <strong>Notice Regarding Forward-Looking Statements<br \/><\/strong>This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical fact contained in this communication, including statements regarding Silexion\u2019s business strategy and ongoing studies are forward-looking statements. These forward-looking statements are generally identified by terminology such as &#8220;may&#8221;, &#8220;should&#8221;, &#8220;could&#8221;, &#8220;might&#8221;, &#8220;plan&#8221;, &#8220;possible&#8221;, &#8220;project&#8221;, &#8220;strive&#8221;, &#8220;budget&#8221;, &#8220;forecast&#8221;, &#8220;expect&#8221;, &#8220;intend&#8221;, &#8220;will&#8221;, &#8220;estimate&#8221;, &#8220;anticipate&#8221;, &#8220;believe&#8221;, &#8220;predict&#8221;, &#8220;potential&#8221; or &#8220;continue&#8221;, or the negatives of these terms or variations of them or similar terminology. Forward-looking statements involve a number of risks, uncertainties, and assumptions, and actual results or events may differ materially from those projected or implied in those statements. Important factors that could cause such differences include, but are not limited to: (i) Silexion\u2019s ability to successfully complete preclinical studies and initiate clinical trials; (ii) Silexion\u2019s strategy, future operations, financial position, projected costs, prospects, and plans; (iii) the impact of the regulatory environment and compliance complexities; (iv) expectations regarding future partnerships or other relationships with third parties; (v) Silexion\u2019s future capital requirements and sources and uses of cash, including its ability to obtain additional capital; and (vi) other risks and uncertainties set forth in the documents filed or to be filed with the SEC by the company, including the Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 18, 2025. Silexion cautions you against placing undue reliance on forward-looking statements, which reflect current beliefs and are based on information currently available as of the date a forward-looking statement is made. Forward-looking statements set forth herein speak only as of the date they are made. Silexion undertakes no obligation to revise forward-looking statements to reflect future events, changes in circumstances, or changes in beliefs, except as otherwise required by law.<\/p>\n<p>\n        <strong>Company Contact<\/strong>\n      <\/p>\n<p>Silexion Therapeutics Corp<em><br \/><\/em>Ms. Mirit Horenshtein Hadar, CFO<br \/>mirit@silexion.com<\/p>\n<p>\n        <strong>Investor Contacts<\/strong>\n      <\/p>\n<p>Chuck Padala<br \/>Lifesci Advisors<br \/>Chuck@lifesciadvisors.com<\/p>\n<p>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=AO47BWuXrBckulSl9tCeMdy1OSCJPix-AzakfE3f0GkqW3UWGtZt4EIW7jRj9evZtaXY1ad4mq8GAiA_BR2zxXOs6RD9ED4kbICelOyPWElBHXDe5McKlnm7ys4zmbM3g-DgUIE_jUfwGqlnGbsHi72Tk0_dC9P01my-ioq4qPEUiqHm6IDjm56fPtkt3jd0S5RzLbmGo5DKssvNIPY49YPJ2qJrWuRVIs5rxtGh1CW6fRaoxK6B-YNjTm8gvbRGp06JyyEMwS9kAgOkb--HZUc2hj6Kd1Lywh2RHb9zsUiTaCrBX4guodEVBjfXH87q84BJ9oIDzHf7AXJ4CCC5nbcJ3SFRu8tnqoTeYvjfeUN0suDM_4gbtKsXQ22K_3Jioxhi39uT2OO8Q5BoI5fyUmaM293axgETreOAiaW7Ceay1mwf8kmdGuvOX8mntqUfsASyVqmSj00mXqw91VQbdJR-h1idu7SC9DsoW2Vslfs1orN5mol4SBjFKViyiktIi0eh_asr-O5lyCWjiysDDjMhoVz0VAUuDZ5pn_sW5WnZ8LPJwQ2HWj7qi1HY9rKverGjJn60G1EH73838r1yqNSZQ5rK_iLfasbvT0h_cnYA1i6z3plDAGAsF3Mt2DLF87VXT_J2n2J1dkVjlwBJQ1OYkSllgTw_s5zvCI-fBOTFZ5v5XQZpO25VQ-igEjCFtOJjTqL-nyHnBBSt24Mvj0K9Vv5I4nWWiNTQeRrjlPBjnD7syDrpLVbQvW2PE60N1YBkoF13rihqstk6vGJopoJknDGZR4CpcmydwVKbhlXTAx6kpGA2wWog-rK9jm4SLe9r31nxRHTbQFkbRbVNUaNyCo97zBvfieZc-8PUphVQbhYeguVDbsDMcwPqp_w3pJ7ritxuNY1HbzzqboQR5g==\" rel=\"nofollow\" target=\"_blank\">Arx | Capital Markets Advisors<\/a><br \/>\n        <br \/>North American Equities Desk<br \/>silexion@arxadvisory.com<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTA1NTEwMCM0MDIwNzkzMTQjMjI5NjY3Mg==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml-eu.globenewswire.com\/media\/OTg4OGNmMWQtNGM4Ny00NzM1LTkyMjMtYWQ0MWJmY2ExODNkLTEzMDgyMjItMjAyNS0wMy0yMS1lbg==\/tiny\/Silexion-Therapeutics-Corp.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Silexion Therapeutics to Present Innovative New Expanded Development Plan for SIL204 at the Industry Leading 2025 NeauxCancer Conference, Following Recently Reported Groundbreaking Preclinical data from Orthotopic Models; Further Details about the Plan to be Reported Shortly Alongside the Presentation Grand Cayman, Cayman Islands, March 21, 2025 (GLOBE NEWSWIRE) &#8212; Silexion Therapeutics Corp. (\u201cSilexion\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers,\u00a0today announced it has completed an expanded development plan for its next-generation siRNA candidate, SIL204, which the company\u2019s management will be presenting at the upcoming Cancer Advocacy Group of Louisiana (CAGLA) NeauxCancer 2025 Conference being held March 27th-29th, 2025 at The Roosevelt New Orleans Hotel in New Orleans, LA. The newly completed strategic &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/silexion-therapeutics-announces-completion-of-innovative-expanded-development-plan-for-sil204-which-will-be-unveiled-at-the-2025-neauxcancer-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-828480","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/silexion-therapeutics-announces-completion-of-innovative-expanded-development-plan-for-sil204-which-will-be-unveiled-at-the-2025-neauxcancer-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Silexion Therapeutics to Present Innovative New Expanded Development Plan for SIL204 at the Industry Leading 2025 NeauxCancer Conference, Following Recently Reported Groundbreaking Preclinical data from Orthotopic Models; Further Details about the Plan to be Reported Shortly Alongside the Presentation Grand Cayman, Cayman Islands, March 21, 2025 (GLOBE NEWSWIRE) &#8212; Silexion Therapeutics Corp. (\u201cSilexion\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers,\u00a0today announced it has completed an expanded development plan for its next-generation siRNA candidate, SIL204, which the company\u2019s management will be presenting at the upcoming Cancer Advocacy Group of Louisiana (CAGLA) NeauxCancer 2025 Conference being held March 27th-29th, 2025 at The Roosevelt New Orleans Hotel in New Orleans, LA. The newly completed strategic &hellip; Continue reading &quot;Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/silexion-therapeutics-announces-completion-of-innovative-expanded-development-plan-for-sil204-which-will-be-unveiled-at-the-2025-neauxcancer-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-21T12:35:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTA1NTEwMCM0MDIwNzkzMTQjMjI5NjY3Mg==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silexion-therapeutics-announces-completion-of-innovative-expanded-development-plan-for-sil204-which-will-be-unveiled-at-the-2025-neauxcancer-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silexion-therapeutics-announces-completion-of-innovative-expanded-development-plan-for-sil204-which-will-be-unveiled-at-the-2025-neauxcancer-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference\",\"datePublished\":\"2025-03-21T12:35:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silexion-therapeutics-announces-completion-of-innovative-expanded-development-plan-for-sil204-which-will-be-unveiled-at-the-2025-neauxcancer-conference\\\/\"},\"wordCount\":738,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silexion-therapeutics-announces-completion-of-innovative-expanded-development-plan-for-sil204-which-will-be-unveiled-at-the-2025-neauxcancer-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTA1NTEwMCM0MDIwNzkzMTQjMjI5NjY3Mg==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silexion-therapeutics-announces-completion-of-innovative-expanded-development-plan-for-sil204-which-will-be-unveiled-at-the-2025-neauxcancer-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silexion-therapeutics-announces-completion-of-innovative-expanded-development-plan-for-sil204-which-will-be-unveiled-at-the-2025-neauxcancer-conference\\\/\",\"name\":\"Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silexion-therapeutics-announces-completion-of-innovative-expanded-development-plan-for-sil204-which-will-be-unveiled-at-the-2025-neauxcancer-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silexion-therapeutics-announces-completion-of-innovative-expanded-development-plan-for-sil204-which-will-be-unveiled-at-the-2025-neauxcancer-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTA1NTEwMCM0MDIwNzkzMTQjMjI5NjY3Mg==\",\"datePublished\":\"2025-03-21T12:35:04+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silexion-therapeutics-announces-completion-of-innovative-expanded-development-plan-for-sil204-which-will-be-unveiled-at-the-2025-neauxcancer-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silexion-therapeutics-announces-completion-of-innovative-expanded-development-plan-for-sil204-which-will-be-unveiled-at-the-2025-neauxcancer-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silexion-therapeutics-announces-completion-of-innovative-expanded-development-plan-for-sil204-which-will-be-unveiled-at-the-2025-neauxcancer-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTA1NTEwMCM0MDIwNzkzMTQjMjI5NjY3Mg==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTA1NTEwMCM0MDIwNzkzMTQjMjI5NjY3Mg==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silexion-therapeutics-announces-completion-of-innovative-expanded-development-plan-for-sil204-which-will-be-unveiled-at-the-2025-neauxcancer-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/silexion-therapeutics-announces-completion-of-innovative-expanded-development-plan-for-sil204-which-will-be-unveiled-at-the-2025-neauxcancer-conference\/","og_locale":"en_US","og_type":"article","og_title":"Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference - Market Newsdesk","og_description":"Silexion Therapeutics to Present Innovative New Expanded Development Plan for SIL204 at the Industry Leading 2025 NeauxCancer Conference, Following Recently Reported Groundbreaking Preclinical data from Orthotopic Models; Further Details about the Plan to be Reported Shortly Alongside the Presentation Grand Cayman, Cayman Islands, March 21, 2025 (GLOBE NEWSWIRE) &#8212; Silexion Therapeutics Corp. (\u201cSilexion\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers,\u00a0today announced it has completed an expanded development plan for its next-generation siRNA candidate, SIL204, which the company\u2019s management will be presenting at the upcoming Cancer Advocacy Group of Louisiana (CAGLA) NeauxCancer 2025 Conference being held March 27th-29th, 2025 at The Roosevelt New Orleans Hotel in New Orleans, LA. The newly completed strategic &hellip; Continue reading \"Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/silexion-therapeutics-announces-completion-of-innovative-expanded-development-plan-for-sil204-which-will-be-unveiled-at-the-2025-neauxcancer-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-21T12:35:04+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTA1NTEwMCM0MDIwNzkzMTQjMjI5NjY3Mg==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silexion-therapeutics-announces-completion-of-innovative-expanded-development-plan-for-sil204-which-will-be-unveiled-at-the-2025-neauxcancer-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silexion-therapeutics-announces-completion-of-innovative-expanded-development-plan-for-sil204-which-will-be-unveiled-at-the-2025-neauxcancer-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference","datePublished":"2025-03-21T12:35:04+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silexion-therapeutics-announces-completion-of-innovative-expanded-development-plan-for-sil204-which-will-be-unveiled-at-the-2025-neauxcancer-conference\/"},"wordCount":738,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silexion-therapeutics-announces-completion-of-innovative-expanded-development-plan-for-sil204-which-will-be-unveiled-at-the-2025-neauxcancer-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTA1NTEwMCM0MDIwNzkzMTQjMjI5NjY3Mg==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silexion-therapeutics-announces-completion-of-innovative-expanded-development-plan-for-sil204-which-will-be-unveiled-at-the-2025-neauxcancer-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/silexion-therapeutics-announces-completion-of-innovative-expanded-development-plan-for-sil204-which-will-be-unveiled-at-the-2025-neauxcancer-conference\/","name":"Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silexion-therapeutics-announces-completion-of-innovative-expanded-development-plan-for-sil204-which-will-be-unveiled-at-the-2025-neauxcancer-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silexion-therapeutics-announces-completion-of-innovative-expanded-development-plan-for-sil204-which-will-be-unveiled-at-the-2025-neauxcancer-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTA1NTEwMCM0MDIwNzkzMTQjMjI5NjY3Mg==","datePublished":"2025-03-21T12:35:04+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silexion-therapeutics-announces-completion-of-innovative-expanded-development-plan-for-sil204-which-will-be-unveiled-at-the-2025-neauxcancer-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/silexion-therapeutics-announces-completion-of-innovative-expanded-development-plan-for-sil204-which-will-be-unveiled-at-the-2025-neauxcancer-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silexion-therapeutics-announces-completion-of-innovative-expanded-development-plan-for-sil204-which-will-be-unveiled-at-the-2025-neauxcancer-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTA1NTEwMCM0MDIwNzkzMTQjMjI5NjY3Mg==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTA1NTEwMCM0MDIwNzkzMTQjMjI5NjY3Mg=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silexion-therapeutics-announces-completion-of-innovative-expanded-development-plan-for-sil204-which-will-be-unveiled-at-the-2025-neauxcancer-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/828480","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=828480"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/828480\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=828480"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=828480"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=828480"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}